[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
June 6, 2001

Labeling Changes for Orlaam

Author Affiliations

Not Available

Not Available

JAMA. 2001;285(21):2705. doi:10.1001/jama.285.21.2705-JFD10005-3-1

The FDA and Roxane Laboratories Inc, Columbus, Ohio, have warned prescribers that use of levomethadyl acetate hydrochloride (Orlaam), a drug for treatment of opiate addiction, has been associated with QT prolongation and severe arrhythmia. The drug's labeling will be changed to emphasize that due to its potential for possibly life-threatening proarrhythmic effects, Orlaam should be used only to treat opiate-dependent patients who fail to show an acceptable response to other adequate treatments of addiction.

First Page Preview View Large
First page PDF preview
First page PDF preview